Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcellaâs AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcellaâs AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering. Source
No articles found.
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
TRACON Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused...
TRACON Pharmaceuticals, Inc. is a clinical stag...
CARROT is a fitness app that rewards users financially for walking and meeting per...
CARROT is a fitness app that rewards users fina...
United Therapeutics Corporation focuses on the strength of a balanced, value-creat...
United Therapeutics Corporation focuses on the ...
Join the National Investor Network and get the latest information with your interests in mind.